AzTrials
AzTrials

Coronary Artery DiseasePOPular HEARTNCT04851418

Pre-hOspital Evaluation of Chest Pain Patients With sUspected Non ST-segment eLevation myocARdial Infarction Using the HEART-score With a Troponin Point-of-care Test

An observational study of Coronary Artery Disease, run by St. Antonius Hospital at 2 sites in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Overcrowding in the emergency department is an increasing problem in hospitals worldwide. Point-of-care Troponin (POC cTn) testing combined with a well investigated risk stratification tool (HEART-score) used in the ambulance may contribute to more rapidly diagnostics of ruling in or ruling out myocardial infarctions… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Coronary Artery Disease
What is being tested?
Possible NSTE-ACS
Type of treatment
Medical device
How many people
650 participants
Where
2 sitesNetherlands
Study dates
1 Sep 2020to Feb 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients with suspected acute coronary syndrome. Total number of patients needed for analysis: n=650

Who may be able to join

  • All out-of-hospital chest pain patients visited by an ambulance
  • Transportation to a hospital with working diagnosis NSTE-ACS
  • Age ≥ 18 years

Who cannot join

  • Comatose state, hemodynamic instability or shock
  • Electrocardiographic ST-segment elevation in the pre-hospital setting
  • No pre-hospital 12-lead electrocardiogram performed or available
  • An obvious non-cardiac cause for the chest pain (trauma, etc.)
  • Suspicion of aortic dissection or pulmonary embolism
  • Cognitive impairment
  • Pregnancy

Trial locations and contacts

2 sites in 1 country.

Netherlands2 sites, 2 recruiting
  • St Antonius Hospital

    Nieuwegein, 3435CL

    J Azzahhafi, MD, +31883201311, j.azzahhafi@antoniusziekenhuis.nl

    Recruiting
  • Diakonessenhuis Utrecht

    Utrecht, 3582KE

    HJ Houtgraaf, MD PhD, +31882507500, researchcardiologie@diakhuis.nl

    M Bontje, MD

    Recruiting

Other trials in Netherlands

About this study

Overcrowding in the emergency department is an increasing problem in hospitals worldwide. Point-of-care Troponin (POC cTn) testing combined with a well investigated risk stratification tool (HEART-score) used in the ambulance may contribute to more rapidly diagnostics of ruling in or ruling out myocardial infarctions (MI) and subsequently reduce unnecessary hospital admissions, total admission time and costs. However, the applicability of the POC cTn and the HEART-score in the pre-hospital setting remains unclear. This study will evaluate this applicability.

Read the detailed description

Co-primary Objectives:

  1. To evaluate the interobserver agreement of the HEART-score performed by ambulance personnel compared to the HEART-score performed by emergency physicians.
  2. To evaluate the diagnostic performance of a strategy based on a pre-hospital HEART-score (with POC cTn testing) or combined with an adjuvant single hs-cTn test at the emergency department to rule-in or rule-out acute coronary syndrome (ACS).
  3. To evaluate the diagnostic performance of (serial) POC cTn testing or combined with hs-cTn testing compared to (serial) hs-cTn testing to rule-in or rule-out MI.
  4. To investigate the feasibility of using the pre-hospital HEART-score and POC cTn in the 0/1 hour algorithm to rule-out ACS. Secondary Objectives:
  5. To evaluate the occurrence of major adverse cardiac events (MACE) in all included patients with a follow up time of 30 days from first medical contact.
  6. To evaluate the patient reported outcome measures (PROMs) in all chest pain patients transported to the hospital at baseline and at 30 days
  7. To perform a cost-analysis of an early diagnostic strategy using the pre-hospital HEART-score

Study design: A prospective, observational, single multicentre study Study population: Total number of patients needed for analysis: n=650 Inclusion criteria: - All out-of-hospital chest pain patients visited by an ambulance

  • Transportation to a hospital with working diagnosis NSTE-ACS
  • Age ≥ 18 years Exclusion criteria: - Comatose state, hemodynamic instability or shock
  • Electrocardiographic ST-segment elevation in the pre-hospital setting treated as STEMI
  • No pre-hospital 12-lead electrocardiogram performed or available
  • An obvious non-cardiac cause for the chest pain (trauma, etc.)
  • Suspicion of aortic dissection or pulmonary embolism
  • Cognitive impairment
  • Pregnancy
  • Suspicion of COVID-19 by ambulance

Study procedures: The HEART-score and the POC cTn will be calculated in all included patients in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of any pre-hospital study measurements (i.e. pre-hospital POC cTn results or calculated pre-hospital HEART-scores) are blinded to the physicians at the ED and will not affect usual care. According to current practice, all patients will be transported to the hospital for further evaluation. At the emergency department (ED) all included patients will undergo regular hs-cTn testing and HEART-score assessment performed by emergency physicians (standard care), and an extra venous blood sample will be drawn for this study. Additional cTn tests (POC and hs-cTn) will be performed in the laboratory.

Main study parameters/endpoints:

  1. HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment)
  2. Final diagnosis of NSTE-ACS at discharge
  3. Myocardial infarction at discharge Secondary study parameters/endpoints:
  4. Composite endpoint (cardiovascular mortality, myocardial infarction, urgent revascularisation) at 30 days
  5. Angina frequency and stability, physical limitations, treatment satisfaction, quality-of-life, cardiac anxiety and depression (SAQ, PHQ-4)

Follow-up: Total follow-up duration is 30 days after initial presentation. Other demographic and clinical parameters at baseline will be taken into account.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All patients will undergo a POC cTn test performed by ambulance personnel. In all patients, two venous blood samples will be drawn in the pre-hospital phase (1x) and at the emergency department (1x). Besides the minimal risks of performing a POC finger prick test, no other risks are involved with study participation. All patients will be asked to fill in questionnaires (i.e. SAQ, PHQ-4) at baseline and at follow-up.

Being tested
Possible NSTE-ACS
Keywords
acute coronary syndrome, point of care troponin, HEART score, NSTE-ACS
Medical subject headings
Coronary Artery Disease, Acute Coronary Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Possible NSTE-ACSDevice

    Also called Point of Care troponin I iSTAT Abbot

    As mentioned in the group description

Study groups in NCT04851418
Study groupRoleWhat they receive
Possible NSTE-ACSAll patients with a suspicion of non-ST-elevation acute coronary syndrome (NSTE-ACS) in the pre-hospital phase are eligible for inclusion. In all included patients, the POC cTn will be performed and the HEART-score will be calculated in the pre-hospital phase. Simultaneously, a venous blood sample will be drawn from the venous access site for later hs-cTn testing. Outcomes of both the POC cTn or the pre-hospital HEART-score will be blinded for the physicians at the emergency department (ED) and will not affect current treatment strategy. All patients with suspected NSTE-ACS will undergo hs-cTn testing and the HEART-score will also be calculated at the ED (T1, standard of care). Here, an additional venous blood sample will be drawn next to routine blood testing testing (T1).
Receives: Device: Possible NSTE-ACS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Heart score agreement

    HEART-score agreement (interobserver variability between pre-hospital and in-hospital HEART-score assessment): the calculated heart score by the ambulance will be subtracted from the calculated score of the emergency department. The minimum value could be -10 and the maximum value could be +10. A positive score means that the ambulance estimates the patient to be sicker or at higher risk. A negative value means that the ED estimates the patient to be sicker/at higher risk for developing major adverse cardiac events.

    Measured: 1 year

  2. Number of participants with final diagnosis of NSTE-ACS

    final diagnosis of NSTE-ACS (non-ST elevation myocardial infarction and unstable angina pectoris) at discharge

    Measured: 1 year

  3. Number of participants with final diagnosis of myocardial infarction at discharge

    Myocardial infarction at discharge

    Measured: 1 year

Secondary outcomes (3)
  1. Number of participants with a composite endpoint

    1. The composite endpoint exists out of cardiovascular mortality, myocardial infarction, urgent revascularisation at 30 days

    Measured: 30 days

  2. Patient reported outcome measure: Seattle Angina questionnaire (SAQ)

    In order to gain information regarding how patients experience their disease, 2 questionnaires will be sent. The first questionnaire; Seattle Angina questionnaire will assess: angina frequency and stability, physical limitations, treatment satisfaction, and quality-of-life.

    Measured: 30 days

  3. Patient reported outcome measure: Patient Health Questionnaire 4

    In order to gain information regarding how patients experience their disease, 2 questionnaires will be sent. The second questionnaire will be the Patient Health Questionnaire 4, will discuss topics such as anxiety, depression and general psychological distress.

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2021
  2. Study start1 Sep 2020
  3. Primary completionJan 2022 (estimated)
  4. Study completionFeb 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
650 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04851418
Sponsor's protocol ID
NL71897.100.19
Acronym
POPular HEART
Status last verified
Apr 2021
First submitted
12 Apr 2021
Last updated
20 Apr 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: nine

Publications

  • Azzahhafi J, Chan Pin Yin DR, Epping M, Bofarid H, Rikken SA, Verhagen T, Boomars R, Radstok A, Houtgraaf J, Bikker A, Ten Berg JM. Pre-hospital evaluation of chest pain patients using the modified HEART-score: rationale and design. Future Cardiol. 2024 Apr 25;20(5-6):241-250. doi: 10.1080/14796678.2024.2356995. Epub 2024 Jun 28.

    PubMed 38940186

Questions about this trial

What is this clinical trial studying?

An observational study of Coronary Artery Disease, run by St. Antonius Hospital at 2 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact JM ten Berg, Prof. Dr. (+31883201232, j.ten.berg@antoniusziekenhuis.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Heart score agreement (time frame: 1 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04851418, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in